References
- Mazereeuw MV, Withrow DR, Nishri ED, et al. Cancer incidence and survival among metis adults in Canada: results from the Canadian census follow-up cohort (1992-2009). Cmaj. 2018;190:E320–e326.
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
- Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30:1–12.
- Borczuk AC. Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. Eur Respir Rev. 2016;25:364–371.
- Li J, You W, Zheng D, et al. A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component. J Cancer Res Clin Oncol. 2018;144:725–734.
- Minoshima Y, Hori T, Okada M, et al. The constitutive centromere component CENP-50 is required for recovery from spindle damage. Mol Cell Biol. 2005;25:10315–10328.
- Rogon C, Ulbricht A, Hesse M, et al. HSP70-binding protein HSPBP1 regulates chaperone expression at a posttranslational level and is essential for spermatogenesis. Mol Biol Cell. 2014;25:2260–2271.
- Feng G, Zhang T, Liu J, et al. MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. FEBS Lett. 2017;591:760–773.
- Winter JM, Gildea DE, Andreas JP, et al. Mapping complex traits in a diversity outbred F1 mouse population identifies germline modifiers of metastasis in human prostate cancer. Cell Syst. 2017;4:31–45 e6.
- Hanissian SH, Teng B, Akbar U, et al. Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma. Brain Res. 2005;1047:56–64.
- Huang DP, Luo RC. MLF1IP is correlated with progression and prognosis in luminal breast cancer. Biochem Biophys Res Commun. 2016;477:923–926.
- Zhang L, Ji G, Shao Y, et al. MLF1 interacting protein: a potential gene therapy target for human prostate cancer? Med Oncol. 2015;32:454.
- Wang S, Liu B, Zhang J, et al. Centromere protein U is a potential target for gene therapy of human bladder cancer. Oncol Rep. 2017;38:735–744.
- Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol. 2013;87:1–11.
- Muller-Tidow C, Diederichs S, Thomas M, et al. Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. Lung Cancer. 2004;45 Suppl 2:S145–50.
- Wu Q, Yang ZF, Wang KJ, et al. AQP8 inhibits colorectal cancer growth and metastasis by down-regulating PI3K/AKT signaling and PCDH7 expression. Am J Cancer Res. 2018;8:266–279.
- Ji C, Guo H, Zhang P, et al. AnnexinA5 promote glioma cell invasion and migration via the PI3K/Akt/NF-kappaB signaling pathway. J Neurooncol. 2018;138:469–478.
- Zhou D, Liu W, Liang S, et al. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway. Cancer Med. 2018;7:1369–1383.
- Sudhakaran PR, Binu S, Soumya SJ. Effect of sarcosine on endothelial function relevant to angiogenesis. J Cancer Res Ther. 2014;10:603–610.
- Zhu J, Yao J, Huang R, et al. Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through PI3K/Akt/mTOR/P70S6K and ERK signaling pathways. Biochem Biophys Res Commun. 2018;498:616–620.
- Hong SY, Yu FX, Luo Y, et al. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Cell Signal. 2016;28:377–383.
- Lu XX, Cao LY, Chen X, et al. PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via downregulating the PI3K/AKT/hTERT pathway in lung adenocarcinoma A549 cells. Biomed Res Int. 2016;2016:2476842.
- Chen J, Yuan J, Zhou L, et al. Regulation of different components from Ophiopogon japonicus on autophagy in human lung adenocarcinoma A549Cells through PI3K/Akt/mTOR signaling pathway. Biomed Pharmacother. 2017;87:118–126.